Oral Immunostimulant Market Overview
Commonly, around 10-15% of the population suffering from a compromised immune system are more exposed to infectious diseases. Oral Immunostimulant enhances the response of the immune system to fight against tumours, infectious diseases, immunodeficiency by making the specific alteration.
The rise in the immunocompromised patient population has led to the development of various oral immunostimulant.It includes a group of synthetic and biological compounds to improve defence system of human body. There have been major focus on preparation, experimental and biological characteristics of oral immunostimulant during last two decades leading to the expansion of oral immunostimulant market.
Covid-19 is projected to impact positively on an oral immunostimulant market and estimated to generate higher revenue. In the Covid-19 pandemic, an oral immunostimulant market is expected to increase product demand due to their ability to boost immunity and protect population from infections including novel coronavirus. In addition, Covid-19 pandemic has risen awareness among the population of primary role of immunity bosting products.
Risk factors such as pollution and radiation exposure has increased risk of sensitization towards various allergens. Frequent allergic reactions due to antibiotics have led to a shift of preference towards oral immunostimulant products in an oral immunostimulant market.
In addition, rising cases of infectious diseases, allergic conditions, cancer and asthma are expected to an exponential growth of oral immunostimulant market. Unavailability of any specific treatment for viral infections such as HIV/AIDS, SARS and other flu is leading the demand of oral immunostimulants.
Generic drugs and biosimilars market competition is expected to hamper the growth of oral immunostimulant market. Discontinuation of various drugs under clinical trials has led to significant revenue loss for oral immunostimulant market due to stringent regulatory policy.
Adverse effects and stringent regulatory policies are projected to be oral immunostimulant market barriers. The global oral immunostimulant market is classified based on active, indication and sales channel.
Interferon and Interleukins are collectively expected to hold major revenue share of an oral immunostimulant market. By indication, cancer segment is expected to generate highest revenue share in an oral immunostimulant market followed by chronic infections.
Among sales channel, hospital pharmacies and retail pharmacies are projected to dominate oral immunostimulant market.Oral immunostimulant market is dominated by North America owing to availability of new therapies. Europe stands second lucrative region in an oral immunostimulant market due to an increased number of research and development activities initiated in the region.
Asia Pacific region is expected to have significant growth for oral immunostimulant market owing to increased prevalence of chronic diseases in the region. The rise in healthcare expenditure in the Latin America region is projected to grow the oral immunostimulant market.
Some key players contributing in an oral immunostimulant market are
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- Merck & Co.
- Eli Lilly and Company
- Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
The research report on oral immunostimulant market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on oral immunostimulant market provides analysis and information according to market segments such as drug class, route of administration, application, and region.
The report covers exhaust analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, Italy, France, U.K, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Oral Immunostimulant Market
Based on Active:
Based On Indication
- Immunodeficiency Disorders
- Chronic infections
- Organ Transplantation
Based On The Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies